

Attorney Pocket No. 0800-0026
USSN 09/932,451

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on January 16, 2003.

By: _____

Sandy Baldwin
Sandy Baldwin

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

OZAWA et al.

Confirmation No.: 3418

Serial No.: 09/932,451

Art Unit: 1635

Filing Date: August 17, 2001

Examiner: B. Whiteman

Title: ADENO-ASSOCIATED VIRUS-MEDIATED DELIVERY OF ANGIOGENIC FACTORS

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
JAN 24 2003
TECH CENTER 1600/2900

PRELIMINARY AMENDMENT

Sir:

Prior to examination of the above-identified application, please insert the following amendments and remarks.

AMENDMENT

In the Specification:

Please replace the paragraph beginning on page 3, line 14 with the following rewritten paragraph:

--One such angiogenic factor, which specifically binds to and activates vascular endothelial cells, is vascular endothelial growth factor (VEGF). VEGF is a potent vasoactive

factor. VEGF is a dimeric protein consisting of two identical subunits. Each subunit contains two cysteine residues that form an intramolecular disulfide bond. VEGF is secreted by a variety of cells, including endothelial cells, and is found in normal cells and tissues. A less abundant, shorter form with a deletion of 44 amino acids between positions 116 and 159 (VEGF₁₂₁), a longer form with an insertion of 24 basic residues